Intra-Cellular Therapies Reports Quarterly Loss, Exceeds Revenue Expectations
Intra-Cellular Therapies Inc. (ITCI) announced a fourth-quarter loss of $16.9 million, or 16 cents per share. This result fell short of analyst expectations, who projected a loss of 5 cents per share.
Despite the loss, ITCI reported revenue of $199.2 million for the quarter, surpassing industry estimates of $192.9 million.
For the full year, the company reported a loss of $74.7 million, or 72 cents per share, on revenue of $680.9 million.